NCT04347122 is a Phase 4 clinical trial of Tranexamic Acid (TXA) in Musculoskeletal Cancer, sponsored by University of Kansas Medical Center.

Who is sponsoring NCT04347122?

NCT04347122 is sponsored by University of Kansas Medical Center.

What drugs are being tested in NCT04347122?

Interventions in NCT04347122: Tranexamic Acid (TXA).

What condition does NCT04347122 study?

NCT04347122 studies Musculoskeletal Cancer, Sarcoma,Soft Tissue.

Is NCT04347122 still recruiting?

NCT04347122 is currently terminated. Last updated 21 May 2025.

Are results published for NCT04347122?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-21 · How we verify

NCT04347122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Terminated Phase 4 Results posted Last updated 21 May 2025

What this trial tests

Phase 4 trial testing Tranexamic Acid (TXA) in Musculoskeletal Cancer in 12 participants. Terminated before completion.

Timeline

28 January 2020

Primary endpoint
18 August 2023

18 August 2023

Quick facts

Lead sponsor	University of Kansas Medical Center
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	12
Start date	28 January 2020
Primary completion	18 August 2023
Estimated completion	18 August 2023
Sites	1 location across United States

Drugs / interventions tested

Tranexamic Acid (TXA) — full drug profile →

Conditions studied

Musculoskeletal Cancer — all drugs for Musculoskeletal Cancer →
Sarcoma,Soft Tissue — all drugs for Sarcoma,Soft Tissue →

Sponsor

University of Kansas Medical Center

Who can join

Adults 18 to 90, any sex, with Musculoskeletal Cancer or Sarcoma,Soft Tissue. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Perioperative Blood Loss Primary · During surgical procedure, 4 to 6 hours

How much blood was lost during surgical process

Group	Value	95% CI
Bony Tumor no TXA Group	283	250 – 350
Soft Tissue Tumor w/ TXA Group	700	100 – 1800
Soft Tissue Tumor With no TXA Group	416	100 – 700

Sponsor's own description

This study intends to determine if any correlation exists between administration of TXA or not to musculoskeletal oncology patients undergoing endoprosthetic reconstruction and blood loss and blood transfusion rates.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of Tranexamic Acid in Cancer Surgery. An Update of Clinical Findings and Ongoing Research.
Zec T, Di Napoli R, Fievez L, Ben Aziz M, et al · · 2022 · cited 6× · PMID 35818514 · DOI 10.2147/jmdh.s337250

Verify or expand the search:

Other trials of Tranexamic Acid (TXA)

Trials testing the same drug.

NCT07115056 — Extended Oral Tranexamic Acid After Anterior Cruciate Ligament Reconstruction · Phase 4 · withdrawn
NCT07332910 — Study the Anti-inflammatory Effect of Tranexamic Acid When Used in Anterior Cruciate Ligament Reconstruction. · Phase 4 · not yet recruiting
NCT07116395 — Prospective Study: TXA, Anticoagulant, Orthopaedic Trauma · Phase 4 · not yet recruiting
NCT07401394 — BAR-TAX - Tranexamic Acid in Bariatric Surgery. · NA · active not recruiting
NCT07212452 — Tranexamic Acid : Nebulization vs IV Route for Hemoptysis · Phase 2, PHASE3 · completed

Other University of Kansas Medical Center trials

Trials by the same sponsor.

NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04347122 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
Last refreshed: 21 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04347122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing